Bifogade filer
PDMI_JM
Kurs
+5,84%
Kurs
+5,84%
Open
0,36
High
0,40
Low
0,36
Close
0,40
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Kalender
| Tid* | ||
| 2025-08-29 | 07:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | Årsstämma |
| 2025-03-18 | 21:30 | Bokslutskommuniké 2024 |
| 2025-01-07 | N/A | Extra Bolagsstämma 2025 |
| 2024-08-26 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-27 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2024-05-24 | - | Årsstämma |
| 2024-03-13 | - | Bokslutskommuniké 2023 |
| 2023-11-22 | - | Extra Bolagsstämma 2023 |
| 2023-08-25 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-30 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2023-05-26 | - | Årsstämma |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-11-03 | - | 15-10 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-06-03 | - | Årsstämma |
| 2022-06-03 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2022-03-29 | - | Bokslutskommuniké 2021 |
| 2022-02-04 | - | Extra Bolagsstämma 2022 |
| 2021-11-03 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-20 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-25 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2021-05-21 | - | Årsstämma |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-23 | - | Bokslutskommuniké 2020 |
| 2020-11-03 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-18 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning OBSRV 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-16 | - | Extra Bolagsstämma 2020 |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-25 | - | Bokslutskommuniké 2019 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OAX Equities |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-11-26 16:44:34
Oslo, 26 November 2024: Observe Medical ASA (the "Company") has been informed
that Jørgen Mann, CEO and primary insider in the Company, has today purchased
100,000 shares in the Company as further specified in the attached notification
form.
Following the purchase, Jørgen Mann holds 600,000 shares in the Company.
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.